SCHEMBL16670470

SCHEMBL16670470

COc1ccc(N(C)C(=O)C(Cc2ccncc2)NC(=O)NS(=O)(=O)c2ccccc2C)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.42
MMP9 P14780 2/20 0.42
MMP1 P03956 1/20 0.42
MMP8 P22894 1/20 0.42
FPR2 P25090 1/20 0.40
USP30 Q70CQ3 3/20 0.40
BMP1 P13497 2/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
HSP90AA1 P07900 1/20 0.39
NAMPT P43490 4/20 0.38
P2RX7 Q99572 1/20 0.37
KDM1A O60341 1/20 0.37
MAOA P21397 1/20 0.37
PTGER4 P35408 1/20 0.36
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16670467 1.00 MMP2 (0.42) MMP2MMP9MMP1MMP8FPR2
SCHEMBL16670299 0.93 FPR2 (0.47) MMP2MMP9MMP1MMP8FPR2
SCHEMBL16670298 0.93 FPR2 (0.47) MMP2MMP9MMP1MMP8FPR2
SCHEMBL16670605 0.91 MMP1 (0.42) MMP2MMP9MMP1MMP8USP30
SCHEMBL16670607 0.91 MMP1 (0.42) MMP2MMP9MMP1MMP8USP30
SCHEMBL16670145 0.88 PTPRB (0.47) MMP2MMP9MMP1MMP8FPR2
SCHEMBL16670144 0.88 PTPRB (0.47) MMP2MMP9MMP1MMP8FPR2
SCHEMBL16670072 0.87 KMT2A (0.42) MMP2MMP9MMP1MMP8KMT2A
SCHEMBL16670070 0.87 KMT2A (0.42) MMP2MMP9MMP1MMP8KMT2A
SCHEMBL16670286 0.87 MMP1 (0.38) MMP2MMP9MMP1MMP8FPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10035760-B2 Inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2018-07-31 US disclosed
US-20160257645-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2016-09-08 US disclosed
EP-3060554-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION Bristol-Myers Squibb Company (US) 2016-08-31 EP disclosed
WO-2015061518-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2015-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257645-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR1E, POLR1G MMP2 1544/4885MMP9 2601/4885MMP1 3144/4885
US-10035760-B2 Inhibitors of human immunodeficiency virus replication EIF2AK2, POLR1G, POLR1E MMP2 1711/4885MMP9 2622/4885MMP1 3205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.